Table 5 Clinical outcomes at prostatectomy

From: A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

 

Placebo

MAG-EPA

N = 65 *

N = 63 *

PSA mean (Std)

6.10 (5.34)

7.90 (8.76)

ISUP Grade Group, n (%)

1 (Gleason 6)

1 (1.5)

3 (4.8)

2 (Gleason 3 + 4)

35 (53.9)

27 (42.9)

3 (Gleason 4 + 3)

23 (35.4)

23 (36.5)

4 (Gleason 8)

2 (3.1)

5 (7.9)

5 (Gleason 9)

4 (6.2)

5 (7.9)

Pathological stage, n (%)

T2 or less (N0)

44 (67.7)

42 (66.7)

T3 or T4 (N0)

15 (23.1)

13 (20.6)

N+ (any T)

6 (9.2)

8 (12.7)

  1. *The sample size is greater than for the main Ki-67 analysis as all patients who underwent radical prostatectomy are included.
  2. p-value from †independent samples t-test, ‡ordinal logistic regression comparing the change over the intervention time between groups, adjusted for PSA, ISUP grade group (2, 3 and 4+), and clinical stage at the biopsy before surgery. PSA prostate-specific antigen, ISUP International Society of Urological Pathology, MAG-EPA monoacylglyceride-conjugated eicosapentaenoic acid.
Back to article page